Esperion Therapeutics (ESPR) is Upgraded by Chardan Capital Markets to Neutral according to the research report released to the investors. The Brokerage Firm has Lowered the Price Target of the company shares to $18 from a previous price target of $29 . Earlier the firm had a rating of Sell on the company shares. The shares recommendation by the Brokerage Firm was released on Sep-30-2015.
Good link, wondering what price of TRVN could be if takes over Morphine as the used pain medication. $100+ I assume
Apple TV Event 9/9/15
The remote also has a Touch feature, which makes it easier to scroll through all of the apps. It has up to a 3-month charge, and can control the volume on your television. The new operating system, tvOS, expands on the app redesign, especially in Netflix (
NFLX ), HBO apps. It makes it easier to switch between apps, and has adapted iOS animations for the TV.
bought $ BLUE in $80's sold at $150, made a killing this looks better
thats all folks
Briefing In Play
ZYNE is a specialty pharmaceutical co focused on developing and commercializing proprietary next-genertion synthetic cannabinoid therapeutics formulated for transdermal delivery.Investors are likely to see this as a buy opportunity, GW Pharma's (GWPH) performance is up over ~1000% since listing in the US.